Navigation Links
Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
Date:2/13/2008

new products-Renvela(R)

(sevelamer carbonate) in the United States, Synvisc-ONE(TM) (hylan

G-F 20) and Cholestagel(R) (colesevelam hydrochloride) in the

European Union, and Elaprase(R) (idursulfase) in Japan-and secured

expanded U.S. labeling for Campath(R) (alemtuzumab) and Thyrogen(R)

(thyrotropin alfa for injection).

-- Reported highly encouraging clinical trial results for two key late

stage product candidates: Mozobil(TM) (plerixafor) for stem-cell

transplantation and alemtuzumab for multiple sclerosis.

Fourth-Quarter 2007 Highlights

-- Revenue increased 21 percent in the fourth quarter to $1.04 billion, up

from $854.2 million in the prior fourth quarter.

-- GAAP net income increased to $78.9 million, or $0.29 per diluted share,

compared with an acquisition-related net loss of $268.2 million, or

$1.02 per diluted share, in the prior fourth quarter.

-- Non-GAAP net income increased 19 percent to $249.2 million, compared

with $209.0 million in the previous fourth quarter.

-- Non-GAAP earnings rose 18 percent to $0.91 per diluted share from

$0.77. The increased operating expenses and decreased interest income

associated with Genzyme's fourth-quarter acquisition of Bioenvision

reduced earnings by $0.01 per diluted share. The company had noted

previously that the impact of this transaction would be reflected in

its fourth-quarter results.

-- Individual product sales for the fourth quarter and the year, along

with expectations for the longer-term growth of Genzyme's business

segments, were detailed in a January 8, 2008, press release coinciding

with the company's presentation at the JPMorgan Healthcare Conference.

"We delivered outstanding financial results last year while continuing to build the company to meet our goa
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine news :

1. Genzyme Receives FDA Response Letter on Synvisc-One(TM)
2. Bioenvision Shareholders Approve Acquisition by Genzyme Corporation
3. Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
4. Genzyme and Bayer Schering Pharma AG, Germany to Present New Data on Alemtuzumab in Multiple Sclerosis at ECTRIMS
5. Delaware Court Approves Bioenvision, Genzyme Joint Petition
6. Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
7. Liquent Insight Publisher 3.6 Delivers Advanced Submission Capabilities
8. March of Dimes Delivers a New Look
9. Independence Blue Cross Delivers Important Reminder to Women during Cervical Cancer Awareness Month
10. PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study
11. Gleevec, the targeted cancer pill, delivers more good news to patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... May 28, 2015 CompanionDx ... company, announces that it will present their integrated ... testing at the annual American Society of Clinical ... sequencing evaluates the DNA in a patient’s tumor ... analyzed for key changes or somatic mutations. Pharmacogenomics ...
(Date:5/28/2015)... Beverly Hills, CA (PRWEB) May 28, 2015 ... a novel interactive keratoconus web application to ... Keratoconus has expanded in the last few years. This ... Even eye doctors are not aware of the nuances ... the Khanna Vision Institute, realized that websites can be ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Sexual ... technology that advances sexual health and wellbeing in ... University of San Francisco (USF) will be the ... sexual assault recording and reporting system. , ... transparent, and confidential reporting experience for college sexual ...
(Date:5/28/2015)... DC (PRWEB) May 28, 2015 ... designing and implementing innovative models of care for ... to support alternative reimbursements and help operationalize contracting ... Optimity also unveils a bi-weekly series of seven ... developing Outcomes Based Contracting. Optimity is a strategy, ...
(Date:5/28/2015)... May 28, 2015 Cancer survivors who ... improvements in physical activity, fitness and quality of life, ... Yale Cancer Center and Jennifer Ligibel, MD, senior physician ... Dana Farber Cancer Institute. The findings will be presented ... (ASCO) Annual Meeting in Chicago. , ...
Breaking Medicine News(10 mins):Health News:CompanionDx® Launches Integrated Genomic Solution at ASCO Meeting 2Health News:Dr.Khanna Announced the Release of an Interactive Web Application for Keratoconus Treatment 2Health News:University of San Francisco Becomes First in the Nation to Adopt College Sexual Assault Reporting System 2Health News:University of San Francisco Becomes First in the Nation to Adopt College Sexual Assault Reporting System 3Health News:Optimity Advisors Now Offers Outcomes Based Contracting Services to Support Engagement Model For New Healthcare Innovative Models of Care 2Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 2Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 3Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 4
... , , , HARRISBURG, ... individuals have received free dental care, valued at nearly $160,000, ... dental insurer United Concordia Dental. , , ... commitment to provide free preventive services to those who cannot ...
... , MIAMI, July 23 Following a ... and a leader in sports nutrition for over 40 years, continues ... weekend Twinlab,s 2009 Mobile Beach Bash ... Miami, Florida. For those eager to show-off their six-pack abs for ...
... , SUNRISE, Fla., July 23 ... delivering intelligent devices and biologics that help monitor, diagnose and ... MARVEL-1 data for presentation at the Heart Failure Society of ... , Chris O,Connor, MD, Head ...
... has shown that risky driving habits are putting young ... of their perceptions about road safety. The study surveyed ... police. Young drivers involved in the study who said ... crash. Previous research has confirmed risky, ...
... Beauty Professionals Encouraged to Share Educational Materials ... , , WASHINGTON, July 23 ... service program created to help women cope with the appearance-related changes of ... Cosmetology Association (NCA) to generate awareness and increase program participation during its ...
... , , , SAN ... OREX ) today announced that it has priced an underwritten ... a price of $7.50 per share. Net proceeds, after estimated ... $70.9 million. Orexigen has granted the underwriter a 30-day option ...
Cached Medicine News:Health News:More than 1,000 Underinsured and Uninsured Individuals Receive Free Dental Care 2Health News:Twinlab's(R) Mobile Beach Bash Heats Up After a Successful Kick-Off of the 2009 RateYourAbs.com Contest 2Health News:Bioheart Announces Acceptance of Marvel-1 Data for Presentation at the Heart Failure Society of America (HFSA) Meeting 2Health News:Bioheart Announces Acceptance of Marvel-1 Data for Presentation at the Heart Failure Society of America (HFSA) Meeting 3Health News:Risky driving puts P-platers at high danger of crash 2Health News:Look Good...Feel Better Launches Salon Awareness Campaign During National Breast Cancer Awareness Month 2Health News:Look Good...Feel Better Launches Salon Awareness Campaign During National Breast Cancer Awareness Month 3Health News:Orexigen(R) Therapeutics Prices Public Offering of Common Stock 2
(Date:5/28/2015)... May 28, 2015  Array BioPharma Inc. (NASDAQ: ... selumetinib (licensed to AstraZeneca) at the 2015 American Society ... held May 29 – June 2, 2015 in ... currently advancing in a total of 6 pivotal trials, ... NEMO (binimetinib monotherapy in NRAS mutant melanoma patients) and ...
(Date:5/28/2015)... -- Eli Lilly and Company (NYSE: LLY ) ... trial that will also be discussed in an ... Oncology (ASCO) Annual Meeting in Chicago ... superiority study of patients with locally-advanced, nonsquamous non-small ... ®  (pemetrexed for injection), in combination with cisplatin ...
(Date:5/28/2015)... , May 28, 2015  Cardinal Health today ... acquire Johnson & Johnson,s Cordis business for $1.944 billion ... after consultations with relevant works councils and trade unions. ... the United States and key non-U.S. countries ... and other customary closing conditions. Headquartered in ...
Breaking Medicine Technology:Array BioPharma Announces Clinical Data Presentations At The 2015 ASCO Annual Meeting 2Array BioPharma Announces Clinical Data Presentations At The 2015 ASCO Annual Meeting 3PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting 2PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting 3PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting 4PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting 5PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting 6PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting 7PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting 8Cardinal Health Binding Offer To Acquire Cordis Accepted 2Cardinal Health Binding Offer To Acquire Cordis Accepted 3Cardinal Health Binding Offer To Acquire Cordis Accepted 4
... www.healthtech.net ), the Ultimate Connectivity Partner in long-term ... Quality Assurance.  In a single system, clinicians use ... to enhance quality care planning and proactive treatment.  ... Reporting for providers wanting to position successful wound ...
... Pharmaceuticals, Inc. (NASDAQ: ARNA ) announced ... Citi 2012 Global Health Care Conference on Wednesday, February 29, ... at the Waldorf=Astoria in New York City. Jack Lief, Arena,s ... corporate overview. A live audio webcast of the ...
Cached Medicine Technology:American HealthTech Announces Comprehensive Wound Management 2Arena Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference 2Arena Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference 3
1.25 mm x 2.5 mm blade. 135 degrees back scratcher. Round handle....
6 mm wide tip. Gentle tapered blade. Designated most popular model or size....
9 mm wide tip. Designated most popular model or size....
4 mm wide tip....
Medicine Products: